Armis Advisers LLC Invests $865,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Armis Advisers LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,092 shares of the company's stock, valued at approximately $865,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Atomi Financial Group Inc. raised its position in shares of IDEXX Laboratories by 28.4% in the 4th quarter. Atomi Financial Group Inc. now owns 864 shares of the company's stock valued at $357,000 after buying an additional 191 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth approximately $16,562,000. Exchange Traded Concepts LLC increased its position in IDEXX Laboratories by 11.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 1,799 shares of the company's stock worth $744,000 after purchasing an additional 187 shares in the last quarter. KFG Wealth Management LLC increased its position in IDEXX Laboratories by 10.0% during the 4th quarter. KFG Wealth Management LLC now owns 1,092 shares of the company's stock worth $451,000 after purchasing an additional 99 shares in the last quarter. Finally, Marshall Financial Group LLC increased its position in IDEXX Laboratories by 5.9% during the 4th quarter. Marshall Financial Group LLC now owns 1,996 shares of the company's stock worth $825,000 after purchasing an additional 112 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.6%

Shares of IDEXX Laboratories stock traded down $3.03 during trading on Friday, hitting $512.52. The company's stock had a trading volume of 1,221,827 shares, compared to its average volume of 652,599. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $530.60. The stock has a market cap of $41.22 billion, a price-to-earnings ratio of 48.03, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The stock has a 50-day moving average price of $449.80 and a two-hundred day moving average price of $437.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the previous year, the firm posted $2.71 earnings per share. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday. Stifel Nicolaus upped their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.